PISCATAWAY, N.J., July 24, 2020 /PRNewswire/ -- GenScript, the world's leading gene synthesis provider, today announced that it will highlight recent innovations using designed mutant libraries to advance neurodegenerative disease treatment at the Protein Engineering Congress USA 2020. During a headline keynote by Dr. Meredith Jackrel of Washington University and a GenScript-hosted panel, experts will review how a first-in-class semiconductor-based DNA synthesis platform is advancing protein engineering. They will also discuss GenScript's precision DNA mutant libraries for improving protein properties such as functional activities and binding affinities for biosynthetic, therapeutic, and diagnostic applications.
"Our novel semiconductor-based DNA synthesis platform allows mutant library construction with precise control over codon usage, thereby enabling the minimization of codon bias and uneven distribution of amino acids as well as preventing the introduction of unwanted or stop codons," said Maung Nyan Win, PhD, Sr. Field Applications Scientist, GenScript. "This customizable codon usage will inherently improve the library quality significantly, saving researchers valuable time and effort during the screening and characterization process, and thus ultimately reducing costs and time to market."
During the Congress:
On July 28 at 12 p.m. EDT, Meredith Jackrel, PhD, assistant professor in the Department of Chemistry at Washington University in St. Louis, presents the headline keynote on behalf of GenScript titled, "Engineering protein disaggregases to counter the protein misfolding that underpins neurodegeneration." Dr. Jackrel discusses utilizing protein disaggregases to counter the misfolding that underpins neurodegeneration in Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. By screening large libraries of Hsp104 variants generated from GenScript's semiconductor-based DNA synthesis platform that comprehensively cover sequence space, Dr. Jackrel aims to uncover variants with improved properties and learn more about the mechanisms of Hsp104 potentiation. Hsp104 is a protein disaggregase from yeast that Dr. Jackrel and team have engineered to counter the misfolding of proteins that aggregate in ALS and Parkinson's disease.
On July 27 at 2:30 p.m. EDT, GenScript hosts the panel "Tailor-Made Mutant Libraries for Precision Engineering," featuring Maung Nyan Win, PhD, Sr. Field Applications Scientist, GenScript; Nicky Caiazza, Co-founder and CSO of Cellibre; and Iman Farasat, Associate Director, Biologics Discovery, The Janssen Pharmaceutical Companies of Johnson & Johnson. The panel will discuss the methods, benefits, and uses of an advanced, arrayed semiconductor-based DNA synthesis platform for construction of high-quality mutant libraries that are devoid of unwanted mutants. The panel will also more broadly discuss the utility of these mutant libraries for biosynthetic and therapeutic applications.
"With the Protein Engineering Congress being the place for showcasing the latest innovations for industrial biocatalysis and synthetic biology-based product development, we are incredibly excited to have market leader GenScript as our headline partner, with Dr. Meredith Jackrel delivering the Day 2 keynote," said Mark Gavhure, Director of Commercial Partnerships for Kisaco Research, sponsor of the event.
The Protein Engineering Congress 2020 gathers scientific and industry leaders to discuss innovations and new techniques in protein and enzyme engineering in industrial applications from pharmaceuticals to specialty chemicals to food and beverages and other consumer goods. Dr. Frances Arnold, recipient of the 2018 Nobel Prize for Chemistry and Linus Pauling Professor, Chemical Engineering, Bioengineering & Biochemistry, will keynote the event.
GenScript is a leading contract research organization providing gene, peptide, protein, CRISPR, and antibody reagents to scientists in over 100 countries worldwide. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science and translational biomedical research, as well as early stage pharmaceutical development. With a mission to improve the health of mankind and nature through biotechnology, the company has developed the best-in-class capacity and capability for producing biological reagents in order to Make Research Easy for all scientists. For more information, visit www.genscript.com.
Contact:CorporateEric Wang, vice president of marketingGenScript(732) 885-9188 ext. firstname.lastname@example.orgMediaSusan ThomasPrincipal, Endpoint Communications(619) email@example.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genscript-highlights-tailor-made-mutant-libraries-for-therapeutic-applications-at-protein-engineering-congress-301099634.html
SOURCE Genscript Biotech Corporation
Wells Fargo & Company (NYSE: WFC) today announced the appointment of six new Corporate Risk leaders as part of its enhanced Risk model to further strengthen the independent oversight of all risk-taking activities and a more comprehensive view of risk across the company. In addition, the company announced that Mike Roemer, the current Chief Compliance Officer, has decided to leave Wells Fargo following a transition period.
"Our new model will strengthen our centralized, independent risk management program, provide greater consistency in how we manage risk across our businesses, and better position us for the future,” said Chief Risk Officer (CRO) Mandy Norton.
The model consists of five line-of-business CROs, along with other teams aligned by risk type, each reporting to Norton. The new leaders, who will all report to Norton, are:
Paula Dominick, who will join Wells Fargo as Chief Compliance Officer in October. Dominick was most recently Chief Compliance Officer of Credit Suisse USA and previously held leadership roles at Bank of America, Goldman Sachs, and Morgan Stanley. In this role, Dominick will be responsible for oversight of all regulatory compliance risks for Wells Fargo.
Brian King, who will join Wells Fargo as CRO for Consumer & Small Business Banking in October. King was most recently CRO and Head of Finance for the Consumer Business at Goldman Sachs and previously held risk leadership roles at JPMorgan Chase.
Ellen Koebler, who will join Wells Fargo as CRO for Commercial Banking in September. Koebler was previously Deputy CRO at Truist, CRO for SunTrust Banks, and held leadership roles at E*Trade, JPMorgan Chase, First Union, and Shell Oil & Shell Chemical Companies.
Prasanna Someshwar, who will join Wells Fargo as CRO for Wealth & Investment Management in October. Someshwar previously held various risk leadership roles at JPMorgan Chase, including CRO and Chief Credit Officer for Wealth Management/Private Bank.
Jeff Colson, who has been named CRO for Finance, joining the risk team in September following a transition period from his current role. Colson was most recently Head of Capital Management at Wells Fargo, and his successor will be named shortly. Colson joined Wells Fargo in 2015, and he previously held executive financial and risk management positions at Bank of America.
Patrick Dillon, who has been named Enterprise Testing & Validation leader, effective immediately. Dillon joined Wells Fargo’s risk organization in 2018 and was previously in compliance leadership roles at PNC Financial Services and Bank of America Merchant Services. In this role, Dillon will lead the team responsible for the development and design of methodologies and standards for review activities across the company and provide strategic leadership of significant enterprise-wide testing programs.
The new CROs will each provide independent, holistic risk leadership and oversight for their respective business lines and functional areas, creating streamlined interaction with independent risk management and a comprehensive view of risks across each of the businesses. The CROs will work in strong partnership with leaders who will continue to oversee market, credit, operational, compliance, strategic, and model risk holistically across the entire company.
"These new leaders bring impressive experience, diverse insights, and strong leadership skills to their roles,” said Norton. "They will each play an important part on the risk leadership team under our newly enhanced organizational structure as we strengthen our independent risk management function and better position how we manage risk for the future.”
The new leaders were named following the May 2020 announcement of the enhanced Corporate Risk model, which noted that Kevin Reen would join Wells Fargo as CRO of Consumer Lending and that Bill Juliano would join Wells Fargo as chief operational risk officer. A search for the new CRO for Corporate & Investment Banking remains underway.
About Wells Fargo
Wells Fargo & Company (NYSE: WFC) is a diversified, community-based financial services company with $1.97 trillion in assets. Wells Fargo’s vision is to satisfy our customers’ financial needs and help them succeed financially. Founded in 1852 and headquartered in San Francisco, Wells Fargo provides banking, investment and mortgage products and services, as well as consumer and commercial finance, through 7,300 locations, more than 13,000 ATMs, the internet (wellsfargo.com) and mobile banking, and has offices in 31 countries and territories to support customers who conduct business in the global economy. With approximately 266,000 team members, Wells Fargo serves one in three households in the United States. Wells Fargo & Company was ranked No. 30 on Fortune’s 2020 rankings of America’s largest corporations. News, insights and perspectives from Wells Fargo are also available at Wells Fargo Stories.
Additional information may be found at www.wellsfargo.com | Twitter: @WellsFargo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200813005834/en/